Anti-allergic activity of 18beta-glycyrrhetinic acid-3-O-beta-D-glucuronide.
D000284:Administration, Oral; D000818:Animals; D018926:Anti-Allergic Agents / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D002460:Cell Line; D003877:Dermatitis, Contact / Q000517:prevention & control; D003907:Dexamethasone / Q000494:pharmacology; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical / Q000379:methods; D020719:Glucuronides / Q000494:pharmacology*; D006034:Glycyrrhetinic Acid / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology*; D019695:Glycyrrhizic Acid / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D007274:Injections, Intraperitoneal; D007422:Intestines / Q000382:microbiology; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009573:Nitrites / Q000037:antagonists & inhibitors / Q000378:metabolism; D010081:Oxazolone / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000276:immunology; D010323:Passive Cutaneous Anaphylaxis / Q000187:drug effects / Q000502:physiology; D013291:Streptococcus / Q000187:drug effects / Q000378:metabolism; D001619:beta-N-Acetylhexosaminidases / Q000037:antagonists & inhibitors / Q000378:metabolism
C492689:18beta-glycyrrhetinic acid-3-O-beta-D-glucuronide; D018926:Anti-Allergic Agents; D020719:Glucuronides; D009573:Nitrites; D010081:Oxazolone; D019695:Glycyrrhizic Acid; D003907:Dexamethasone; D001619:beta-N-Acetylhexosaminidases; D006034:Glycyrrhetinic Acid